Bristol Myers’ (BMY) sBLA for Orencia Gets FDA Priority Review Posted byZacks Equity Research August 24, 2021 Leave a comment on Bristol Myers’ (BMY) sBLA for Orencia Gets FDA Priority Review The FDA accepts Bristol Myers’ (BMY) sBLA for Orencia under a priority review to prevent moderate to severe acute graft versus host disease. A verdict…